Fibrosis Pulmonar
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment.
Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study.
Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
Infografía – Estudio Solaris. Pirfenidona LP en secuelas Post-COVID.
Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis.
The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs.
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies.
Role of pirfenidone in TGF‑β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection: a theoretical perspective.
Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis.
Post-COVID-19 Pulmonary Fibrosis.
Irreversibility of Pulmonary Fibrosis.
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebocontrolled phase II trial
Primer Consenso Mexicano sobre Fibrosis Pulmonar Idiopática
